Price
Frequently asked questions
What is Valneva's market capitalization?
What is the Earnings Per Share (EPS) for Valneva?
What are the analyst ratings and target price for Valneva's stock?
What is Valneva's revenue over the trailing twelve months?
What is the EBITDA for Valneva?
What is the free cash flow of Valneva?
What is the 5-year beta of Valneva's stock?
How many employees does Valneva have, and what sector and industry does it belong to?
What is the free float of Valneva's shares?
Financials
Market Cap
$414.91M5Y beta
0.71EPS (TTM)
-$0.0606Free Float
119.89MRevenue (TTM)
$168.39MEBITDA (TTM)
$46.51MFree Cashflow (TTM)
-$179.14MPricing
Analyst Ratings
The price target is $9.984 and the stock is covered by 8 analysts.
Buy
7
Hold
1
Sell
0
Information
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
695
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker